Chinese medicine has been launched in the United States. On December 22, 2021, CSPC Pharmaceutical Group announced that the patented drug "Xuanning" developed by the group to treat hypertension has just passed the review by the U.S. Food and Drug Administration. evaluation, becoming the first Chinese local innovative drug to be fully approved for marketing. This means that when the drug is licensed for global sales, it will also be eligible to become one of the international standards that similar drugs must refer to when they are re-marketed.